NASDAQ:COLL Collegium Pharmaceutical (COLL) Stock Forecast, Price & News $22.35 -0.25 (-1.11%) (As of 09/29/2023 08:52 PM ET) Add Compare Share Share Today's Range$22.27▼$22.6550-Day Range$21.55▼$24.2852-Week Range$15.92▼$30.22Volume323,400 shsAverage Volume376,674 shsMarket Capitalization$776.22 millionP/E RatioN/ADividend YieldN/APrice Target$35.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Collegium Pharmaceutical MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside58.8% Upside$35.50 Price TargetShort InterestBearish20.49% of Float Sold ShortDividend StrengthN/ASustainability-2.78Upright™ Environmental ScoreNews Sentiment1.02Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth17.34%From $4.73 to $5.55 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.12 out of 5 starsMedical Sector494th out of 968 stocksPharmaceutical Preparations Industry232nd out of 452 stocks 3.3 Analyst's Opinion Consensus RatingCollegium Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.50, Collegium Pharmaceutical has a forecasted upside of 58.8% from its current price of $22.35.Amount of Analyst CoverageCollegium Pharmaceutical has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted20.49% of the float of Collegium Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverCollegium Pharmaceutical has a short interest ratio ("days to cover") of 23.6, which indicates bearish sentiment.Change versus previous monthShort interest in Collegium Pharmaceutical has recently decreased by 6.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCollegium Pharmaceutical has received a 26.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Tapendatol" and "Oxycodone" products. See details.Environmental SustainabilityThe Environmental Impact score for Collegium Pharmaceutical is -2.78. Previous Next 2.8 News and Social Media Coverage News SentimentCollegium Pharmaceutical has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Collegium Pharmaceutical this week, compared to 2 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.69% of the stock of Collegium Pharmaceutical is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Collegium Pharmaceutical are expected to grow by 17.34% in the coming year, from $4.73 to $5.55 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is -60.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is -60.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 3.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Collegium Pharmaceutical (NASDAQ:COLL) StockCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Read More COLL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COLL Stock News HeadlinesSeptember 29, 2023 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Shares Cross Below 50 Day Moving Average of $23.15September 29, 2023 | americanbankingnews.comCollegium Pharmaceutical (NASDAQ:COLL) Stock Price Crosses Below 50 Day Moving Average of $23.15October 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. August 28, 2023 | finance.yahoo.comCollegium Announces 10 Poster Presentations at PAINWeek Conference 2023August 25, 2023 | msn.comNeedham Maintains Collegium Pharmaceutical (COLL) Buy RecommendationAugust 25, 2023 | markets.businessinsider.comNeedham Maintains Buy Rating for Collegium Pharmaceutical: Here's What You Need To KnowAugust 24, 2023 | msn.comCollegium pain med Nucynta gets US market exclusivity extensionAugust 24, 2023 | finance.yahoo.comCollegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026October 2, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. August 16, 2023 | stocknews.comWhich of These 3 Pharma Stocks Are a Buy?August 12, 2023 | msn.comCollegium Pharmaceutical: Pipeline Continues As Share Buyback InitiatesAugust 11, 2023 | seekingalpha.comWith 30% Returns On Capital Deployed At 4.4x Earnings, Collegium Is A BuyAugust 7, 2023 | finance.yahoo.comCollegium Announces $50 Million Accelerated Share Repurchase ProgramAugust 4, 2023 | finanznachrichten.deCollegium Pharmaceutical, Inc.: Collegium Reports Record 1H'23 Net Revenue of $280.3 Million, Up 35% Year-over-YearAugust 4, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for Collegium Pharmaceutical (COLL)August 4, 2023 | finance.yahoo.comHere's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q2 EarningsAugust 3, 2023 | seekingalpha.comCollegium Pharmaceutical, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 3, 2023 | msn.comCollegium Pharmaceutical Non-GAAP EPS of $1.26 beats by $0.04, revenue of $135.5M misses by $2.91MAugust 3, 2023 | finance.yahoo.comCollegium Reports Record 1H’23 Net Revenue of $280.3 Million, Up 35% Year-over-YearAugust 3, 2023 | finance.yahoo.comCollegium Pharmaceutical (COLL) Q2 Earnings Beat EstimatesAugust 1, 2023 | finance.yahoo.comCOLL - Collegium Pharmaceutical, Inc.July 20, 2023 | finance.yahoo.comCollegium to Report Second Quarter 2023 Financial Results on August 3, 2023July 7, 2023 | finance.yahoo.comCollegium Pharmaceutical (NASDAQ:COLL) shareholders have earned a 8.5% CAGR over the last three yearsJune 22, 2023 | finance.yahoo.comDo Options Traders Know Something About Collegium Pharmaceutical (COLL) Stock We Don't?June 9, 2023 | finance.yahoo.comControlled Release Drug Delivery Global Market Report 2023June 7, 2023 | markets.businessinsider.comBausch Health Companies (BHC) Receives a Hold from Piper SandlerJune 1, 2023 | finance.yahoo.comCollegium to Participate in Jefferies Healthcare ConferenceSee More Headlines Receive COLL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address COLL Company Calendar Last Earnings8/03/2023Today10/02/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:COLL CUSIPN/A CIK1267565 Webwww.collegiumpharma.com Phone(781) 713-3699FaxN/AEmployees207Year FoundedN/APrice Target and Rating Average Stock Price Forecast$35.50 High Stock Price Forecast$36.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside+58.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E Ratio4.73 P/E GrowthN/ANet Income$-25,000,000.00 Net Margins-2.08% Pretax Margin-1.14% Return on Equity87.81% Return on Assets14.12% Debt Debt-to-Equity Ratio2.85 Current Ratio1.24 Quick Ratio1.18 Sales & Book Value Annual Sales$463.93 million Price / Sales1.67 Cash Flow$8.19 per share Price / Cash Flow2.73 Book Value$5.80 per share Price / Book3.85Miscellaneous Outstanding Shares34,730,000Free Float33,452,000Market Cap$776.22 million OptionableOptionable Beta0.84 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Michael Thomas Heffernan B.S. Pharm (Age 59)R.Ph., Co-Founder & Chairman Comp: $110kMr. Joseph J. Ciaffoni (Age 52)Pres, CEO & Director Comp: $1.69MMs. Colleen Tupper (Age 47)Exec. VP & CFO Comp: $848.29kMs. Shirley R. Kuhlmann (Age 39)Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. Comp: $842.9kMr. Scott Dreyer (Age 51)Exec. VP & Chief Commercial Officer Comp: $746.58kDr. Thomas B. Smith FAAFP (Age 62)M.D., Exec. VP & Chief Medical Officer Comp: $692.91kDr. Christopher Shayne James M.D.VP of Investor RelationsMr. Bart J. DunnExec. VP of Strategy & Corp. Devel.Mr. Scott SudduthHead of Technical OperationsMore ExecutivesKey CompetitorsNewAmsterdam PharmaNASDAQ:NAMSPOINT Biopharma GlobalNASDAQ:PNTCassava SciencesNASDAQ:SAVAArcturus TherapeuticsNASDAQ:ARCTVerve TherapeuticsNASDAQ:VERVView All CompetitorsInsiders & InstitutionsCalifornia State Teachers Retirement SystemBought 1,438 shares on 8/21/2023Ownership: 0.121%Teachers Retirement System of The State of KentuckyBought 598 shares on 8/21/2023Ownership: 0.031%Nuveen Asset Management LLCSold 77,833 shares on 8/16/2023Ownership: 0.267%Eventide Asset Management LLCBought 1,120 shares on 8/15/2023Ownership: 7.576%Citadel Advisors LLCSold 1,600 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions COLL Stock - Frequently Asked Questions Should I buy or sell Collegium Pharmaceutical stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" COLL shares. View COLL analyst ratings or view top-rated stocks. What is Collegium Pharmaceutical's stock price forecast for 2023? 2 Wall Street research analysts have issued 1-year price objectives for Collegium Pharmaceutical's stock. Their COLL share price forecasts range from $35.00 to $36.00. On average, they predict the company's share price to reach $35.50 in the next year. This suggests a possible upside of 58.8% from the stock's current price. View analysts price targets for COLL or view top-rated stocks among Wall Street analysts. How have COLL shares performed in 2023? Collegium Pharmaceutical's stock was trading at $23.20 at the beginning of the year. Since then, COLL stock has decreased by 3.7% and is now trading at $22.35. View the best growth stocks for 2023 here. Are investors shorting Collegium Pharmaceutical? Collegium Pharmaceutical saw a drop in short interest in September. As of September 15th, there was short interest totaling 6,920,000 shares, a drop of 6.5% from the August 31st total of 7,400,000 shares. Based on an average trading volume of 293,000 shares, the days-to-cover ratio is presently 23.6 days. Currently, 20.5% of the shares of the stock are sold short. View Collegium Pharmaceutical's Short Interest. When is Collegium Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our COLL earnings forecast. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announced its earnings results on Thursday, August, 3rd. The specialty pharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.11 by $0.02. The specialty pharmaceutical company had revenue of $135.55 million for the quarter, compared to the consensus estimate of $137.98 million. Collegium Pharmaceutical had a positive trailing twelve-month return on equity of 87.81% and a negative net margin of 2.08%. What ETFs hold Collegium Pharmaceutical's stock? ETFs with the largest weight of Collegium Pharmaceutical (NASDAQ:COLL) stock in their portfolio include First Trust Dow Jones Select Microcap Index Fund (FDM), Inspire Fidelis Multi Factor ETF (FDLS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has Collegium Pharmaceutical issued on next quarter's earnings? Collegium Pharmaceutical issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $565.00 million-$580.00 million, compared to the consensus revenue estimate of $570.46 million. What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO? 6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH). When did Collegium Pharmaceutical IPO? (COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. What is Collegium Pharmaceutical's stock symbol? Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL." How do I buy shares of Collegium Pharmaceutical? Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Collegium Pharmaceutical's stock price today? One share of COLL stock can currently be purchased for approximately $22.35. How much money does Collegium Pharmaceutical make? Collegium Pharmaceutical (NASDAQ:COLL) has a market capitalization of $776.22 million and generates $463.93 million in revenue each year. The specialty pharmaceutical company earns $-25,000,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. How many employees does Collegium Pharmaceutical have? The company employs 207 workers across the globe. How can I contact Collegium Pharmaceutical? Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The official website for the company is www.collegiumpharma.com. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at info@collegiumpharma.com. This page (NASDAQ:COLL) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.